| Bioactivity | OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research[1]. |
| Sequence | d-(Gly-Gln-Ser-Glu-His-His-Met-Arg-Val-Tyr-Ser-Phe) |
| Shortening | d-(GQSEHHMRVYSF) |
| Formula | C64H92N20O19S |
| Molar Mass | 1477.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li W, et al. An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy[J]. Journal of Controlled Release, 2021, 334: 376-388. |